Clinical Trial Update: PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) [Phase 1, Phase 2]

View source ↗

Summary

The PRO-MERIT trial, a Phase 1/2 prostate cancer messenger RNA immunotherapy developed by BioNTech, has been terminated with results posted in March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PRO-MERIT

Snippet

Sponsor: BioNTech SE | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-03-20